ClinicalTrials.gg

Program

dencatistat

Its studies are mostly in Lymphoma, B-Cell · Thrombocythemia, Essential, led by Step Pharma, SAS.

Furthest: phase 2, since Jun 30, 20223 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Step Pharma, SAS33 open or runningphase 2since Jun 30, 2022Jun 30, 2022Dec 2026phase 1 · NCT06297525

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2022First study: phase 2 study in Lymphoma, B-CellFirst studyNCT05463263 · 180 planned · United States, France, United Kingdom
  2. Feb 29, 2024Phase 1 study in Solid TumorNCT06297525 · 70 planned · United States, France, United Kingdom
  3. Jan 8, 2025Phase 2 study in Thrombocythemia, EssentialNCT06786234 · 50 planned · France, United Kingdom

Ahead

  1. Dec 2026Primary completion: phase 1 study in Solid TumorNCT06297525
  2. Dec 2026Primary completion: phase 2 study in Lymphoma, B-CellNCT05463263
  3. Jun 30, 2028Primary completion: phase 2 study in Thrombocythemia, EssentialNCT06786234

TargetBeta

CTPS1 →read by rule
“An orally bioavailable, small molecule inhibitor of cytidine triphosphate synthase 1 (CTPS1), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06786234Thrombocythemia, Essential · France, United Kingdom2RecruitingJun 30, 202850
NCT06297525Solid Tumor · United States, France, United Kingdom1RecruitingDec 202670
NCT05463263Lymphoma, B-Cell · United States, France, United Kingdom2RecruitingDec 2026180

How it is read

Names in the registry

  • “STP938”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.